Research Paper

HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B

Chong Zhang, Zhengrong Yang, Ziyi Wang, Xiaoguang Dou, Qiuju Sheng, Yanwei Li, Chao Han, Yang Ding

Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, 110022, China

Corresponding author: Yang Ding. Address: Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, 110022, China. Email: yding903@sina.com

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.08.29; Accepted: 2020.01.08; Published: 2020.02.04

Abstract

Objective: The proportion of hepatitis e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients in China has increased rapidly. However, the response of these patients to peginterferon (peg-IFN) treatment is poor, and the antiviral treatment strategies are inconsistent. This study aimed to investigate the role of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) in early prediction of response in HBeAg-negative CHB patients receiving peg-IFN α-2a.

Patients and Methods: Treatment-naïve HBeAg-negative patients were involved in this prospective study during 2014–2018. The HBV DNA and HBsAg were quantified at baseline and during treatment (weeks 12, 24 and 48) in sera. The factors associated with HBV DNA undetectable and HBsAg <100 IU/ml at treatment 48 weeks were assessed.

Results: This study involved 45 patients. There was HBV DNA undetectable in 36 cases (80%), including 19 (52.8%) with HBsAg <100 IU/ml at week 48. The HBV DNA <2.0 log10 IU/ml at week 24 (PPV = 96.9%, NPV = 66.7%, P = 0.018) was an independent predictor of HBV DNA undetectable at week 48. The HBsAg <800 IU/ml at baseline (PPV = 92.1%, NPV = 69.7%, P = 0.054) and HBsAg decline >5.00-fold at week 24 (PPV = 83.3%, NPV = 77.8%, P = 0.038) were independent predictors of HBsAg <100 IU/ml and HBV DNA undetectable at week 48.

Conclusion: Early on-treatment quantification of HBV DNA and HBsAg in patients with HBeAg-negative CHB treated with peg-IFN α-2a may help identify those likely to be cured by this method and optimize therapy strategies.

Key words: chronic hepatitis B, HBeAg, prospective study

Introduction

Chronic hepatitis B virus (HBV) infection is a health problem affecting over 240 million people worldwide [1]. Nearly 40% of those with chronic HBV infection who do not receive antiviral therapy will deteriorate into cirrhosis or hepatocellular carcinoma (HCC), with a high risk of liver function decompensation [2]. The incidence of hepatitis e antigen (HBeAg)-negative chronic hepatitis B (CHB) in China has increased rapidly in recent years [3]. It represents a late phase in the course of the infection, accompanied by much more serious fibrosis and easily deteriorates in comparison with HBeAg-positive CHB [4]. Thus, HBeAg-negative patients need much more active treatment.

Guidelines worldwide currently recommend peginterferon (peg-IFN), entecavir and tenofovir as the first-line treatment for CHB [5–7]. Compared with nucleos(t)ide analogs, peg-IFN has advantages such as shorter therapy course, lower drug resistance rate and an effect of immunomodulatory function. Therefore, peg-IFN is preferred for HBeAg-negative patients.
In the last decade, much research has focused on optimizing CHB therapy strategies. Antiviral therapy is expected to achieve long-term good prognosis through short-term treatment and it is important to explore associative factors used as prognostic prediction. It was shown that HBV DNA inhibition and clearance and low levels of hepatitis B s antigen (HBsAg) are important factors in delaying disease progression [8–11]. Notably, HBsAg quantitative level plays an important role in predicting the efficacy of antiviral therapy and the long-term prognosis of the disease. Several studies have suggested that HBsAg level is an independent predictor for progression of CHB, and a low level of HBsAg (<100 IU/ml) is followed by reduced risk of disease deterioration [11–13].

However, only a small portion of HBeAg-negative patients achieve sustained response when treated with peg-IFN. It is therefore a major challenge to identify the patients likely to benefit from peg-IFN therapy as early as possible in the treatment course. Several recent studies suggested that age and gender of patients, HBV genotype and dynamics of HBsAg and HBV DNA in the treatment course can be used to predict the response to interferon-based therapy [14,15]. However, most of these studies were registered randomized controlled trials, and the data were mostly from Caucasians and African Americans. Our study is a prospective, real-world, observational study aimed at HBeAg-negative CHB patients from China to determine the role of early on-treatment quantitative HBV DNA and HBsAg in prediction of response of patients treated with peg-IFN α-2a.

Patients and Methods

Patients

Treatment-naïve HBeAg-negative CHB patients were involved in this study during 2014–2018. The patients were from China and aged 18–65 years. Patients eligible for this study had been positive for HBsAg for >6 months, were HBeAg-negative, had a serum HBV DNA level of ≥2000 IU/ml, had repeated elevated serum alanine aminotransferase (ALT) levels (>2 but ≤10 times the upper limit of the normal range (ULN)] and had serum total bilirubin level ≤2 ULN [5]. Exclusion criteria were as follows: history of anti-HBV treatment; coinfection with hepatitis C virus, hepatitis D virus or human immunodeficiency virus; other acute or chronic liver diseases; pregnancy; mental illness; thyroid disease, autoimmune disease, retinal disease, serious infection and severe acute or chronic cardiopulmonary insufficiency.

All patients received 180 μg of peg-IFN α-2a weekly, with duration of 48 weeks followed up every 4 weeks. A decision whether to continue treatment or change strategy after 48 weeks was made according to the response during therapy. For patients whose HBV DNA has dropped to the lower limit of detection and HBsAg has dropped to 10 IU/mL at 48 weeks of treatment with Peg-IFN, the treatment can be extended to 72 weeks or longer to pursue clinical cure. Otherwise, it is recommended to stop Peg-IFN and treat with nucleoside analogs for the long term [16].

All patients gave written informed consent. This study was approved by The Ethical Committees of Shengjing Hospital.

Laboratory measurements

The HBV viral load and HBsAg and ALT levels of patients were determined at the baseline and during treatment (weeks 12, 24 and 48) in the sera. Serum HBV DNA was measured by Roche COBAS AmpliPrep/COBAS TaqMan HBV Quantitative Test, Version 2.0 (Roche Diagnostics, Indianapolis, IN), with dynamic range 20–1.7 E8 IU/ml. The HBsAg level was measured by Abbott Architect Plus i2000 analyzer (Abbott, Abbott Park, IL), with a lower limit of detection of 0.05 IU/ml. The ALT level was determined by Beckman AU5800 automatic biochemical analyzer (Beckman Coulter Inc., Atlanta, GA).

Statistical analysis

Statistical software SPSS 21.0 (SPSS, Chicago, IL) was used for statistical processing and analysis. Continuous variables were analyzed for normal distribution using the Kolmogorov–Smirnov test. Normally distributed data are presented as mean ± standard deviation (SD) and their inter-group comparison was performed with independent sample t test or t' test; the non-normally distributed data are presented as median (P250, P750) and their inter-group comparison was performed with the Mann–Whitney U test. Categorical variables are presented as number and percentage and their inter-group comparison was performed with χ² test. Significant differences required P < 0.05. The predictive analysis of results was performed using the receiver operating characteristic curve (ROC) and logistic regression, with P < 0.1 indicating a significant difference.

Results

Baseline characteristics

During the observation period, a total of 45 patients completed 48 weeks of peg-IFN α-2a therapy, of whom 33 were male (73.3%). The mean age was 41.47 ± 10.43 (mean ± SD) years. At the baseline, serum HBV viral load was 5.33 log10 IU/ml (SD: 1.45.
log_{10} IU/ml, range: 3.38–7.78 log_{10} IU/ml), and serum HBsAg level was 3.15 log_{10} IU/ml (SD: 0.61 log_{10} IU/ml, range: 1.38–4.35 log_{10} IU/ml).

**Factors associated with HBV DNA undetectable at treatment week 48**

After 48 weeks of peg-IFN α-2a treatment, HBV viral loads were undetectable in 36 cases, making an undetectable rate of 80%. Serum HBV viral loads at baseline, weeks 12 and 24 of patients with HBV DNA undetectable at week 48 were significantly lower than those with HBV DNA detectable at week 48 (5.03±1.29 (mean ± SD) log_{10} IU/ml, P = 0.004; 1.61 ± 1.34 (mean ±SD) log_{10} IU/ml, P<0.001; 0 (0, 1.54) [median (interquartile range)] log_{10} IU/ml, P < 0.001; respectively). There was a significantly lower HBsAg level at week 24 in HBV DNA undetectable patients than in HBV DNA detectable patients (2.19 ± 1.20 vs 3.20 ± 0.54 log_{10} IU/ml, P = 0.017). Furthermore, although non-significant, HBV DNA undetectable cases had much lower HBsAg levels at both baseline and week 12, and much higher HBsAg decline at week 24 from the baseline (7.59-fold vs 2.00-fold, P = 0.055), compared with HBV DNA detectable cases (Table 1).

**Prediction of HBV DNA undetectable at treatment week 48**

Using ROC, we analyzed the cutoff values of HBV DNA and HBsAg levels during baseline and weeks 12 and 24 of therapy to predict HBV DNA undetectable at week 48. The serum HBV DNA of <5.5 log_{10} IU/ml at baseline (P = 0.005), <3.3 log_{10} IU/ml at week 12 (P = 0.001) and <2.0 log_{10} IU/ml at week 24 (P < 0.001), and serum HBsAg level <1400 IU/ml at week 24 (P = 0.010), could predict HBV DNA undetectable after 48 weeks of peg-IFN α-2a treatment. The HBV DNA of <2.0 log_{10} IU/ml at week 24 was an independent predictor for HBV DNA undetectable at week 48, with positive predictive value (PPV) of 96.9% and negative predictive value (NPV) of 66.7% (OR = 29.7, P = 0.018).

**Table 1. Characteristics of HBV DNA undetectable and detectable patients at treatment week 48.**

| Characteristics | HBV DNA undetectable (n = 36) | HBV DNA detectable (n = 9) | P   |
|-----------------|-------------------------------|-----------------------------|-----|
| Age (years)     | 41.78 ± 9.88                  | 40.22 ± 13.01               | 0.694|
| Sex (male/female) | 27/9                          | 6/3                         | 0.682|
| Baseline HBsAg (log_{10} IU/ml) | 3.07 ± 0.61             | 3.51 ± 0.53                | 0.051|
| HBV DNA (log_{10} IU/ml) | 5.03 ± 1.29              | 6.65 ± 1.49                | 0.004|
| Week 12 HBsAg (log_{10} IU/ml) | 2.63 ± 0.97            | 3.25 ± 0.53                | 0.075|
| HBsAg decline (log_{10} IU/ml)† | 0.23 (0.05, 0.68)       | 0.11 (-0.07, 0.57)         | 0.348|
| HBV DNA (log_{10} IU/ml) | 1.61 ± 1.34            | 3.78 ± 1.54                | <0.001|
| HBV DNA decline (log_{10} IU/ml) | 3.42 ± 1.10         | 2.78 ± 1.30                | 0.130|
| Week 24 HBsAg (log_{10} IU/ml) | 2.19 ± 1.20         | 3.20 ± 0.54                | 0.017|
| HBsAg decline (log_{10} IU/ml) | 0.88 ± 0.85           | 0.30 ± 0.42                | 0.055|
| HBV DNA (log_{10} IU/ml)† | 0 (0, 1.54)           | 2.55 (2.05, 4.06)          | <0.001|
| HBV DNA decline (log_{10} IU/ml) | 4.30 ± 1.35        | 3.53 ± 1.54                | 0.241|

HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen. †Expressed as median (interquartile range). Other continuous variables expressed as mean ± SD.

**Figure 1.** ROC analysis for HBV DNA level at baseline and weeks 12 and 24, and HBsAg at week 24, for prediction of HBV DNA undetectable at week 48 during peg-IFN α-2a therapy.
Figure 2. ROC analysis for HBsAg level at baseline and weeks 12 and 24, and HBsAg decline from baseline to weeks 12 and 24, for prediction of HBsAg < 100 IU/ml in patients with HBV DNA undetectable at week 48 during peg-IFN α-2a therapy.

Table 2. Characteristics of patients with HBsAg <100 IU/ml and ≥100 IU/ml at treatment week 48.

| Characteristics                                                                 | HBsAg <100 IU/ml (n = 19) | HBsAg ≥100 IU/ml (n = 17) | P     |
|-------------------------------------------------------------------------------|---------------------------|---------------------------|-------|
| Age (years)                                                                   | 40.68 ± 10.43             | 43.00 ± 9.38              | 0.491 |
| Sex (male/female)                                                             | 15/4                      | 12/5                      | 0.423 |
| Baseline HBsAg (log$_{10}$ IU/ml)                                             | 2.79 ± 0.65               | 3.37 ± 0.38               | 0.003 |
| HBV DNA (log$_{10}$ IU/ml)                                                    | 4.84 ± 1.26               | 5.24 ± 1.34               | 0.358 |
| Week 12 HBsAg (log$_{10}$ IU/ml)                                              | 2.17 ± 1.11               | 3.15 ± 0.37               | 0.001 |
| HBsAg decline (log$_{10}$ IU/ml)†                                              | 0.31 (0.14, 0.99)          | 0.12 (0.01, 0.25)         | 0.042 |
| HBV DNA (log$_{10}$ IU/ml)                                                    | 1.35 ± 1.20               | 1.92 ± 1.45               | 0.187 |
| HBV DNA decline (log$_{10}$ IU/ml)                                            | 3.51 ± 0.98               | 3.32 ± 1.31               | 0.606 |
| Week 24 HBsAg (log$_{10}$ IU/ml)                                              | 1.51 ± 1.28               | 2.93 ± 0.38               | <0.001|
| HBsAg decline (log$_{10}$ IU/ml)†                                              | 1.28 ± 0.94               | 0.43 ± 0.40               | 0.001 |
| HBV DNA (log$_{10}$ IU/ml)                                                    | 0 (0.131)                 | 0 (0.191)                 | 0.219 |
| HBV DNA decline (log$_{10}$ IU/ml)                                            | 4.35 ± 1.13               | 4.23 ± 1.62               | 0.784 |

HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen. †Expressed as median (interquartile range). Other continuous variables expressed as mean ± SD

Factors associated with HBsAg <100 IU/ml at treatment week 48

In 36 cases of HBV DNA undetectable after 48 weeks of peg-IFN α-2a treatment, serum HBsAg levels in 19 cases (52.8%) were <100 IU/ml. Compared with patients with HBsAg ≥100 IU/ml at treatment week 48, HBsAg levels in patients with HBsAg <100 IU/ml were significantly lower at baseline and weeks 12 and 24 [2.79 ± 0.65 vs 3.37 ± 0.38 (mean ± SD) log$_{10}$ IU/ml, P = 0.003; 2.17 ± 1.11 vs 3.15 ± 0.37 (mean ± SD) log$_{10}$ IU/ml, P = 0.001; 1.51 ± 1.28 vs 2.93 ± 0.38 (mean ± SD) log$_{10}$ IU/ml, P < 0.001; respectively]. Furthermore, HBsAg declines from baseline after 12 and 24 weeks of treatment were significantly higher in patients with HBsAg <100 IU/ml at week 48 compared with those HBsAg ≥100 IU/ml [0.31 (0.14, 0.99) vs 0.12 (0.01, 0.25) [median (interquartile range)] log$_{10}$ IU/ml, P = 0.042, for week 12; 1.28 ± 0.94 vs 0.43 ± 0.40 (mean ± SD) log$_{10}$ IU/ml, P = 0.001, for week 24; respectively] (Table 2).

Prediction of HBsAg <100 IU/ml at treatment week 48

The cutoff values of HBV DNA and HBsAg levels during baseline and weeks 12 and 24 of therapy to predict HBsAg < 100 IU/ml at week 48 were analyzed using ROC. The serum HBsAg of <785 IU/ml at baseline (P = 0.004), <481 IU/ml at week 12 (P = 0.001) and <305 IU/ml at week 24 (P < 0.001) could be used to predict HBsAg <100 IU/ml in patients with HBV DNA undetectable after 48 weeks of peg-IFN α-2a therapy. Similarly, HBsAg declines of >1.78-fold from baseline to week 12 (P = 0.041) and >4.68-fold to week 24 (P = 0.001) compared with baseline could also be used as predictors (Fig. 2).

Using the results of ROC analysis, the approximate predictive values for the critical values of various predictive indicators were used to conduct univariate and multivariate analyses of binary logistic regression. The serum HBsAg levels <800 IU/ml at baseline (P = 0.004), <500 IU/ml at week 12 (P < 0.001)
and <300 IU/ml at week 24 (P < 0.001), together with HBsAg decline >2.00-fold from baseline to week 12 (P = 0.048) and >5.00-fold to week 24 (P = 0.001) could predict HBsAg <100 IU/ml in patients with HBV DNA undetectable after 48 weeks of peg-IFN α-2a treatment. Among them, HBsAg <800 IU/ml (PPV = 92.1%, NPV = 69.7%, OR = 29.5, P = 0.038) and HBsAg decline of >5.00-fold to week 24 (PPV = 83.3%, NPV = 77.8%, OR = 43.16, P = 0.038) were independent predictors for HBsAg <100 IU/ml at week 48; meanwhile, HBV DNA was undetectable.

Discussion

Peginterferon as a first-line drug for CHB has been widely used in treatment of HBeAg-positive and -negative patients. For HBeAg-negative patients, the Chinese guidelines recommend the adjustment of treatment strategy based on HBsAg decline from baseline [5]; however, HBeAg-negative CHB patients tend to have a lower baseline level of HBsAg. This may lead to missing the opportunity to continue peg-IFN therapy for some patients, if the clinical medication regimen is only adjusted according to HBsAg decline. Consequently, we not only considered the HBsAg declines but also their absolute values in our research, with the aim to provide new solutions for antiviral therapy in HBeAg-negative patients.

Many studies have suggested that inhibition and clearance of HBV DNA and a low level of HBsAg are the important factors delaying disease progression and the accumulative incidence rate of HCC is positively correlated with serum HBV DNA level [8-11]. HBsAg level is an independent predictive factor for progression of CHB, and a lower level of HBsAg (<100 IU/ml) can decrease the risk of disease deterioration [11,17,18]. Additionally, the recommended treatment course of peg-IFN is 48 weeks in the Chinese guidelines [5]. Thus, the relevant monitoring period in this study was up to treatment week 48, when HBV DNA was undetectable and HBsAg <100 IU/ml.

Many studies have shown that serum HBV DNA and HBsAg levels at treatment weeks 12 and 24 have higher predictive values for viral response [19-21]. Therefore, we evaluated the effects of serum levels of HBV DNA and HBsAg at baseline and weeks 12 and 24 on prediction of HBV DNA undetectable and HBsAg <100 IU/ml after therapy for 48 weeks. Reducing the time of detection can greatly reduce the economic and living burden for patients.

In the study by Peng et al., HBV DNA levels at baseline and at treatment weeks 12 and 24 were independent predictors for viral response at week 48, the cut-offs for which were 4.3 (OR = 7, P = 0.02), 3.0 (OR = 7.9, P = 0.02) and 2.5 log<sub>10</sub> copies/ml (OR = 22.3, P = 0.008), respectively [22]. Another large-scale clinical study demonstrated that lower HBV viral load and higher ALT levels at baseline were important factors for acquiring SVR at follow-up week 24 after peg-IFN treatment [23]. In the present study, serum HBV DNA of <5.5 log<sub>10</sub> IU/ml at baseline, <3.3 log<sub>10</sub> IU/ml at week 12 and <2.0 log<sub>10</sub> IU/ml at week 24, and serum HBsAg <1400 IU/ml at week 24, could predict HBV DNA undetectable at week 48 of peg-IFN α-2a treatment. This suggests that detection of HBV DNA or HBsAg during treatment is critical for predicting the negative conversion of HBV DNA at 48 weeks. Notably, HBV DNA <2 log<sub>10</sub> IU/ml at week 24 was an independent predictor with a greater level of significance.

We found that HBsAg <800 IU/ml at baseline, <500 IU/ml at week 12 and <300 IU/ml at week 24, together with HBsAg decline of >2.00-fold from baseline to week 12 and >5.00-fold to week 24, could predict HBsAg <100 IU/ml at week 48 of peg-IFN α-2a treatment. This indicates that HBsAg and its decline from the baseline at each test time during treatment are important for predicting low HBsAg levels at week 48. In particular, baseline HBsAg levels and 24-week HBsAg decline are significant. Briefly, for an HBeAg-negative CHB patient treated with peg-IFN, it was only necessary to detect HBsAg levels at baseline and week 24 of treatment. The level of baseline <800 IU/ml means that the patient has a 92.1% probability of HBsAg <100 IU/ml at baseline <800 IU/ml at week 24, while HBsAg decline at week 24 by >5.00-fold from baseline means that the patient has an 83.3% probability of HBsAg <100 IU/ml at week 48 of treatment.

For HBeAg-negative CHB, the current guidelines recommend the use of log values of HBV DNA and HBsAg decline to predict the effect of peg-IFN therapy. However, most of the research population comprises Europeans and Americans. In this study, the subjects were a Chinese population with genotypes B and C, and quantitative HBV DNA and HBsAg were predictors. We analyzed the prediction of HBV DNA undetectable and HBsAg <100 IU/ml at week 48 and obtained the critical values of these indicators. The limitation is that this study is single-centered and of small sample size. Currently, some patients are receiving the treatment and follow-up in the clinic of our hospital, and a subsequent study with a larger sample size will be conducted. Because only four patients demonstrated the negative conversion of HBsAg at treatment week 48, the prediction of HBsAg clearance was not analyzed. At the end of the treatment, nine patients with HBsAg <10 IU/ml were still under the follow-up
for the prolonged course of treatment, and efficacy will be further observed.

Conclusion

In conclusion, for HBeAg-negative CHB patients treated with peg-IFN α-2a, baseline is the first checkpoint to understand their initial treatment values. Based on whether the baseline HBsAg is <800 IU/ml, a preliminary prediction is made on whether HBsAg would be <100 IU/ml at 48 weeks of treatment. The second checkpoint to predict is at treatment week 2, at which HBV DNA <2.0 log_{10} IU/ml can be used to predict whether HBV DNA is negative at week 48, and reduction of HBsAg >5.00-fold from baseline can be used to predict whether HBsAg is <100 IU/ml at week 48.

Abbreviations

HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HBeAg: hepatitis e antigen; CHB: chronic hepatitis B; peg-IFN: peginterferon; HBsAg: hepatitis B s antigen; ALT: alanine aminotransferase; ULN: upper limit of the normal range; SD: standard deviation; ROC: receiver operating characteristic curve; PPV: positive predictive value; NPV: negative predictive value; SVR: sustained viral response.

Acknowledgements

This work was supported by the China National Science and Technology Major Project of Infectious Diseases Control during the 13th-Five Year Plan Period (2017ZX10201201, 2017ZX10202202), the Liaoning Provincial Local Professional Technology Innovation Platform Construction Project (20160070 13), the Liaoning Provincial Natural Science Foundation (20180550096), and the Medical Science Study Foundation (YWJKJJHKYJJ-B181004).

Ethics approval

The study protocol was approved by The Ethical Committee of Shengjing Hospital. The study was conducted in accordance with the ethical principles laid down in the Declaration of Helsinki.

Informed consent

All patients provided their written informed consent.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546–1555.
2. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA 2018;319:1802–1813.
3. Li H, Ye Z, Gao X, Zhang L, Yao X, Gu J, et al. Disu Y Tanggang capsule improving liver histological response for patients with HBeAg-negative chronic hepatitis B: a randomized controlled clinical trial. Am J Transl Res 2018;10:1511–1521.
4. Zhu SS, Dong Y, Wang LM, Xu ZQ, Chen DW, Gan Y, et al. A retrospective study on the liver pathological characteristics and the effect of antiviral treatment for 1 to 7 years old children with hepatitis B e antigen negative chronic hepatitis B. Zhonghua Er Ke Za Zhi 2016;54:587–591.
5. Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, et al. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297–318.
6. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370–398.
7. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1–98.
8. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660–1665.
9. Yang HL, Yuan MF, Chan HL, Hu KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568–574.
10. Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, et al. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol 2018;6:25–34.
11. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum HBsAg surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441–450.
12. Tseng TC, Liu CJ, Chen CL, Wang CC, Su TH, Kuo SF, et al. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 2012;205:54–63.
13. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140–1149.e3; quiz e13–14.
14. Zhou F, Yang F, Wang J, Mao K, Qi X, Huang Y, et al. Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients. Medicine (Baltimore) 2015;94:e270.
15. Masaki K, Suzuki F, Hara T, Kawamura Y, Sezaki H, Hosaka T, et al. Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. Virol J 2015;12:225.
16. Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, et al. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2018;6:1–10.
17. Liu F, Wang XW, Chen L, Hu P, Ren H, Hu HD. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 2016;43:1253–1261.
18. Yang Y, Gao J, Li HL, Zheng W, Yang G, Zhang W, et al. Dose-response association between hepatitis B surface antigen levels and liver cancer risk in Chinese men and women. Int J Cancer 2016;139:355–362.
19. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151–1157.
20. Charatcharoenwityha P, Supeepiasarnnawel W, Piratvisuth T, Thongsawat S, Sanpajit T, Chomprasertsuk S, et al. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. J Gastroenterol Hepatol 2016;31:1874–1881.
21. Boglione L, Cusato J, Cariti G, Di Perri G, D’Avolio A. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. Antiviral Res 2016;136:32–36.
22. Peng CY, Lai HC, Li YF, Su WP, Chuang PY, Kao JT. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2012;35:458–468.
23. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699 - 705.